The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Xu, Xiaoming ^a   Jin, Huiying ^b   Liu, Yafang ^c   Liu, Li ^b   Wu, Qiong ^d   Guo, Yaxiong ^a   Yu, Lina ^a   Liu, Zhijing ^a   Zhang, Ting ^a   Zhang, Xiaowei ^a   Dong, Xueyan ^a   Quan, Chengshi ^a  

^a Basic Medical College   (China)

^b Jilin Oil Field General Hospital   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Breast invasive ductal carcinomas; Claudin 6; DNA methyltransferase 1; Histone deacetylase 1; Methyl cpG binding protein 2

Indexed keywords

CLAUDIN; CLAUDIN 6; DMAP1 PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE 1; METHYL CPG BINDING PROTEIN 2; REPRESSOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CANCER GRADING; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLAUDINS; FEMALE; HISTONE DEACETYLASE 1; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; METHYL-CPG-BINDING PROTEIN 2; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84858953077     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-33     Document Type: Article

References (42)

1. Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011, 365(11):1025-1032. 10.1056/NEJMcp1101540, 21916640.
2. Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22(13):2021-2033. 10.1038/sj.onc.1206199, 12673207.
3. Escudero-Esparza A, Jiang WG, Martin TA. The Claudin family and its role in cancer and metastasis. Front Biosci 2011, 16:1069-1083. 10.2741/3736, 21196219.
4. Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, Tamura A, Igarashi M, Endo T, Takeuchi K, et al. Predicted expansion of the claudin multigene family. FEBS Lett 2011, 585(4):606-612. 10.1016/j.febslet.2011.01.028, 21276448.
5. Turksen K, Troy TC. Junctions gone bad: claudins and loss of the barrier in cancer. Biochim Biophys Acta 2011, 1816(1):73-79.
6. Turksen K, Troy TC. Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev Dyn 2001, 222(2):292-300. 10.1002/dvdy.1174, 11668606.
7. Findley MK, Koval M. Regulation and roles for claudin-family tight junction proteins. IUBMB Life 2009, 61(4):431-437. 10.1002/iub.175, 2708117, 19319969.
8. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, Song YS, Marquez VE, Nephew KP, Shin YK. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31(6):974-983. 10.1093/carcin/bgp336, 2878357, 20053926.
9. Honda H, Pazin MJ, Ji H, Wernyj RP, Morin PJ. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 2006, 281(30):21433-21444. 10.1074/jbc.M603767200, 16714763.
10. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159. 10.1056/NEJMra072067, 18337604.
11. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010, 15(1):5-17. 10.1007/s10911-010-9165-1, 2824126, 20101446.
12. Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001, 8(2):115-127. 10.1677/erc.0.0080115, 11446343.
13. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128(4):693-705. 10.1016/j.cell.2007.02.005, 17320507.
14. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435(7046):1262-1266. 10.1038/nature03672, 15988529.
15. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002, 21(11):2672-2681. 10.1093/emboj/21.11.2672, 126040, 12032080.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002, 41(3A):154-161.
17. Yafang L, Qiong W, Yue R, Xiaoming X, Lina Y, Mingzi Z, Ting Z, Yulin L, Chengshi Q. Role of Estrogen Receptor-alpha in the Regulation of Claudin-6 Expression in Breast Cancer Cells. J Breast Cancer 2011, 14(1):20-27. 10.4048/jbc.2011.14.1.20, 3148509, 21847390.
18. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T, Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 2005, 96(7):403-408. 10.1111/j.1349-7006.2005.00071.x, 16053511.
19. Saito Y, Kanai Y, Nakagawa T, Sakamoto M, Saito H, Ishii H, Hirohashi S. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003, 105(4):527-532. 10.1002/ijc.11127, 12712445.
20. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y. Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 2007, 72(1-2):69-74. 10.1159/000111106, 18004079.
21. Quan C, Lu SJ. Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 2003, 24(10):1593-1599. 10.1093/carcin/bgg129, 12896909.
22. Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y, Quan C. Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev 2010, 19(3):186-194. 10.1097/CEJ.0b013e328337210e, 20215972.
23. Osanai M, Murata M, Chiba H, Kojima T, Sawada N. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Sci 2007, 98(10):1557-1562. 10.1111/j.1349-7006.2007.00569.x, 17645772.
24. Bird A. The methyl-CpG-binding protein MeCP2 and neurological disease. Biochem Soc Trans 2008, 36(Pt 4):575-583.
25. Hua X, Yu L, Huang X, Liao Z, Xian Q. Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol 2011, 6:111. 10.1186/1746-1596-6-111, 3228672, 22067528.
26. Antonelli M, Hasselblatt M, Haberler C, Di Giannatale A, Garre ML, Donofrio V, Lauriola L, Ridola V, Arcella A, Fruhwald M, et al. Claudin-6 is of limited sensitivity and specificity for the diagnosis of atypical teratoid/rhabdoid tumors. Brain Pathol 2011, 21(5):558-563.
27. Ouban A, Ahmed AA. Claudins in human cancer: a review. Histol Histopathol 2010, 25(1):83-90.
28. Schneppenheim R, Fruhwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010, 86(2):279-284. 10.1016/j.ajhg.2010.01.013, 2820190, 20137775.
29. Brenner C, Fuks F. DNA methyltransferases: facts, clues, mysteries. Curr Top Microbiol Immunol 2006, 301:45-66. 10.1007/3-540-31390-7_3, 16570845.
30. Bogdanovic O, Veenstra GJ. DNA methylation and methyl-CpG binding proteins: developmental requirements and function. Chromosoma 2009, 118(5):549-565. 10.1007/s00412-009-0221-9, 2729420, 19506892.
31. Wojdacz TK, Thestrup BB, Overgaard J, Hansen LL. Methylation of cancer related genes in tumor and peripheral blood DNA from the same breast cancer patient as two independent events. Diagn Pathol 2011, 6:116. 10.1186/1746-1596-6-116, 3253685, 22129206.
32. Muller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Muller-Holzner E, Marth C, Widschwendter M. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer 2003, 89(10):1934-1939. 10.1038/sj.bjc.6601392, 2394448, 14612906.
33. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997, 88(4):471-481. 10.1016/S0092-8674(00)81887-5, 9038338.
34. Magdinier F, Billard LM, Wittmann G, Frappart L, Benchaib M, Lenoir GM, Guerin JF, Dante R. Regional methylation of the 5' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J 2000, 14(11):1585-1594. 10.1096/fj.14.11.1585, 10928993.
35. Wischnewski F, Friese O, Pantel K, Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007, 5(7):749-759. 10.1158/1541-7786.MCR-06-0364, 17634428.
36. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19(2):187-191. 10.1038/561, 9620779.
37. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393(6683):386-389. 10.1038/30764, 9620804.
38. Segre CV, Chiocca S. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2010, 2011:690848. 3004424, 21197454.
39. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9(2):139-148. 10.1016/S1470-2045(08)70004-4, 18207460.
40. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14(6):1669-1677. 10.1158/1078-0432.CCR-07-0990, 18347167.
41. Miyake K, Yoshizumi T, Imura S, Sugimoto K, Batmunkh E, Kanemura H, Morine Y, Shimada M. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas 2008, 36(3):e1-e9. 10.1097/MPA.0b013e31815f2c2a, 18437073.
42. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90(1):15-23. 10.1007/s10549-004-1668-2, 15770522.